Ready to Start?

Swipe through policies to balance the biotech social contract and help both patients and biotech innovators right from your phone!

Play → Quick swipe mode • No sign-up
Full simulation: available on a laptop or desktop computer.
On a tablet? Rotate to landscape mode to unlock the full game.
nopatientleftbehind.org
No Patient Left Behind (NPLB) Logo

The Biotech Social Contract Game - Tuillet

Biotech Investment
0/8
Patient Affordability
0/6
Policies Enacted
0/20

Patient
Affordability

Policies that remove financial barriers at the pharmacy counter & secure timely generics

Affordability Pillar 0/6

20 policies left on the docket

Biotech
Investment

Policies that protect high-risk R&D, patent exclusivities & reward innovation

Investment Pillar 0/8
Your Political Capital
REJECTED
Policy Trash Can
nopatientleftbehind.org Game by Polina Tuillet & Paul Tuillet
The Biotech Social Contract

Can affordability & innovation coexist?

Welcome to the NPLB Biotech Social Contract Game! You are a healthcare policymaker. Prove that biotech innovation investment and affordability for patients can live in harmony by sorting each policy from the docket into its primary goal. Choose wisely!

Each policy belongs to one of these categories:

Drag the top policy card into your chosen zone (or tap to select), then press Enact Policies to see if it fits.
Each misplaced policy costs one of your 5 lives.

Once finished, you will see that these policies don't contradict each other, instead together, they balance and establish The Biotech Social Contract!

Try the swipe mode
Shredded Policies

Oh, no!

You left your patients (and voters) behind. Try again!
Without the right balance between biotech investment and affordability for patients, the biotech social contract breaks down.
Biotech Social Contract in Action

Congratulations, Policymaker!

You proved that biotech innovation investment and patient affordability can coexist harmoniously. True policy balances access to innovative treatments with long-term generic pipelines, a finite reward for innovators, followed by inexpensive generics for society, forever.

Learn More at No Patient Left Behind